

Review Article

Alpha-to-beta cell trans-differentiation for treatment of diabetes

Mohamed Saleh^{1,2}, George K. Gittes¹ and  Krishna Prasad¹

¹Division of Pediatric Surgery, UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA 15224, U.S.A.; ²Division of Pediatric Endocrinology, UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA 15224, U.S.A.

Correspondence: Krishna Prasad (prasadank@upmc.edu)



Diabetes mellitus is a significant cause of morbidity and mortality in the United States and worldwide. According to the CDC, in 2017, ~34.2 million of the American population had diabetes. Also, in 2017, diabetes was the seventh leading cause of death and has become the number one biomedical financial burden in the United States. Insulin replacement therapy and medications that increase insulin secretion and improve insulin sensitivity are the main therapies used to treat diabetes. Unfortunately, there is currently no radical cure for the different types of diabetes. Loss of β cell mass is the end result that leads to both type 1 and type 2 diabetes. In the past decade, there has been an increased effort to develop therapeutic strategies to replace the lost β cell mass and restore insulin secretion. α cells have recently become an attractive target for replacing the lost β cell mass, which could eventually be a potential strategy to cure diabetes. This review highlights the advantages of using α cells as a source for generating new β cells, the various investigative approaches to convert α cells into insulin-producing cells, and the future prospects and problems of this promising diabetes therapeutic strategy.

Introduction

Type 1 diabetes is a chronic disease characterized by autoimmune-mediated destruction of the insulin-producing β cells in the pancreas [1]. Destruction of β cells leads to insulin deficiency, hyperglycemia, and eventually the development of clinical diabetes. The treatment options for type 1 diabetes are limited to insulin replacement therapy. While, type 2 diabetes results from long-standing insulin resistance [2]. In type 2 diabetes, β cell mass is reduced by 40–60% compared with weight-matched controls [3,4]. The underlying etiology of β cell mass loss in type 2 diabetes is thought to be due to an increase in β -cell apoptosis rate [5], as chronic exposure to insulin resistance imposes a high workload on β cells in order to meet the higher demand for insulin secretion, which makes β cells vulnerable to endoplasmic reticulum (ER) stress [6,7]. Besides the decreased β cells in patients with type 2 diabetes, β -cell dysfunction also occurs early in the natural course of type 2 diabetes, with a decline in β cell function of 75–80% in subjects in the upper third of impaired glucose tolerance (2 h plasma glucose = 180–199 mg/dl) [6,8,9]. Additionally, reduced first-phase insulin secretion was found to be the earliest and most detrimental defect in β cells in humans with impaired glucose tolerance (prediabetes) and type 2 diabetes [10,11].

There is no cure for type 1 and type 2 diabetes. The prevailing therapeutic approaches to type 2 diabetes have focused on drugs that either improve insulin resistance or increase insulin secretion and decrease glucagon secretion [12]. However, these medications increase the risk of side effects such as dysregulated insulin secretion, weight gain, hypoglycemia, and gastrointestinal, renal, and cardiovascular side effects [13,14]. Although the pathophysiology of type 1 and type 2 diabetes are different, loss of β cell mass with subsequent insulin deficiency represents the end result that directly causes diabetes. Therefore, a better therapeutic strategy would be to enhance β cell mass and restore insulin secretory capacity, which might cure different types of diabetes.

Received: 2 September 2021

Revised: 4 November 2021

Accepted: 10 November 2021

Version of Record published:
9 December 2021

Key transcription factors involved in the development of β cells

In the developing pancreas, cellular differentiation and lineage selection are regulated by a cascade of transcription factors and signaling molecules that coordinate the timing and development of the exocrine and endocrine cells from progenitor cells (Figure 1). The differentiation of endocrine cell types in the pancreas changes throughout embryogenesis. Specifically, α cells are the first to form, with glucagon-positive cells appearing early




Figure 1. Mouse pancreas development originates from the foregut endoderm under the control of several transcription and growth factors, specifically *pdx1*.

Loss of *pdx1* prevents the formation of the pancreas, while overexpression of endocrine-specific transcription factor, *ngn3*, in foregut endoderm will result in an immature pancreas containing only α cells. Loss of *ngn3* expression in these cells prevents endocrine development. *pdx1* positive progenitors develop both trunk and tip progenitors, *ngn3* expression in trunk progenitor then leads those into an endocrine lineage and generates all four endocrine cell types. *Pdx1* and *MafA* expression in select endocrine progenitors gave way to β cells, while *MafB* expression is required for α cell formation. Forced expression on *pdx1*, *MafA*, and *ngn3* in acinar cells reprograms them into β cells, while forced expression of *pdx1* and *MafA* in α cells converts them to β cells.

in the developing mouse pancreas at E9.5, with a subset of these cells co-express insulin [15,16]. This finding suggests that pancreatic endocrine progenitor cells co-express a set of islet hormones whose expression is selectively up or down-regulated as the endocrine lineage selection occurs. Beyond α cells, other types of endocrine cells, including β cells, are not generated in significant numbers in mouse until E13.5 or later [17].

In mice, early embryonic *pdx1* positive cells represent progenitors of all of the mature endocrine and exocrine pancreatic cells [18]. *Pdx1* expression becomes limited to β cells late in the development of the murine pancreas as β cells mature [19]. Also, *pdx1* is known to regulate the insulin genes in rodents [20]. Besides, *PDX1* is required for normal β cell function, and loss of its expression from one allele in adult humans causes diabetes [21,22]. Conditional deletion of *pdx1* in the developing β cells in rodents results in hyperglycemia, reduced number of β cells and an increased number of α cells [23,24]. In the developing mouse pancreas, all endocrine cells develop from neurogenin-3 (*ngn3*) positive endocrine progenitor cells [18,25]. *Ngn3* [a class A Basic Helix-Loop-Helix Protein (bHLH)] is expressed in duct-like epithelial cells that are centrally located within the developing mouse pancreas; as these cells differentiate, they down-regulate *ngn3* and aggregate into proto-islet structures [26]. Loss of function mutation of *ngn3* prevents endocrine development and leads to death in mice postnatally [25,27–29]. Although it is critical for all pancreatic endocrine cell identity, forced expression of *ngn3* early during the mouse pancreas development under the *pdx1* promoter led to the formation of a premature cluster of endocrine cells containing only α cells [26], suggesting a role for other factors besides *ngn3* later in development for proper endocrine development and specification.

The Maf family proteins, *MafA*, and *MafB* have a central role in the late development and maturation of endocrine cells in rodents [30–32]. In the embryonic mouse pancreas, a significant portion of insulin-positive cells express *MafB*, and as part of the β cell maturation process, these cells transitioned through a *MafB* and *MafA* double-positive phase (insulin intermediate cells) followed by full maturation to a *MafB* negative and *MafA* positive β cells. This transition of β cells to become *MafA* positive only coincides with increased *pdx1* expression in these mature cells [33]. *MafB* (–/–) null mutant embryonic pancreas had reduced numbers of insulin and glucagon-positive cells, yet, the total number of endocrine cells appeared to remain the same [34,35]. Unlike mice, adult human islet β cells express *MAFB* [36]. Human progenitor stem cells lacking *MAFB* expression failed to differentiate into α or β cells, but formed delta and pancreatic polypeptide cells [36].

The *MafA* null mutant mouse showed that *MafA* is necessary for maturation but not for the specification of pancreatic β cells. [33]. Losing *MafA* during the development of mouse pancreas did not alter the proportion of insulin-positive cells at birth, suggesting normal development and lineage selection [33]. However, the *MafA* deficient mice developed diabetes postnatally, suggesting that *MafA* regulates maturation and is required for glucose-responsive expression of insulin in adult β cells [33]. To this point, *MafA* interacts with *NeuroD1* and *Pdx1* [29] to activate the insulin gene in mice [30]. Besides *Pdx-1* and *MafA*, in rodents, the mature β -cell expresses *Pax4*, *Nkx 2.2*, and *Nkx 6.1*, which are also required to maintain normal function [37].

Non-endocrine cells as a source of new β cells

There have been several attempts in the past to convert non-endocrine cells into insulin-producing cells [38,39], including viral-mediated expression of transcription factors in human hepatocytes [38], mouse gastrointestinal cells [40], and acinar cells [41,42]. Ectopic *PDX1* expression in adult human liver cells induced the development of functional insulin-producing cells; these cells when transplanted under the renal capsule of diabetic, immunodeficient mice ameliorated hyperglycemia [43]. Also, *In vivo* recombinant-adenovirus-mediated gene transfer of *pdx1* into liver cells ameliorated hyperglycemia in diabetic mice treated with streptozotocin [44]. Furthermore, treatment with exendin-4 (Glucagon-like peptide agonist) enhanced the proliferation and maturation of *PDX1*-expressing human liver cells toward a β cell phenotype [45]. In addition, plasmid-based *pdx1*, *MafA*, and *ngn3* (PMN) gene delivery into the inferior vena cava transiently induced insulin transcripts in rat livers [46]. Also, systemic administration of a single adenoviral vector encoding *pdx1*, *MafA*, and *ngn3* factors reprogrammed duct-like SOX9-positive cells in the liver into insulin-producing cells and improved hyperglycemia in non-obese diabetic/severe combined immunodeficient (NOD/SCID) mice treated with streptozotocin [47]. Notably, those insulin-producing duct-like cells showed some degree of glucose responsiveness *ex vivo* [47]. In immunocompetent mice, adenoviral vector-mediated PMN delivery transiently induced insulin-producing SOX9-positive duct-like cells in the liver [48].

Acinar cells were another cell type targeted as a potential source of new insulin-producing cells. Forced expression of *ngn3* alone in mouse acinar cells induced conversion into delta cells, while forced *ngn3* and *MafA* expression converted acinar cells into α -like cells [41]. However, a combination of the three transcription

factors, *ngn3*, *MafA* and *pdx1*, converted the acinar cells into beta-like cells and improved hyperglycemia in toxin-induced-diabetic mice [41,42].

Besides pancreas acinar cells and liver cells, several studies have targeted gastrointestinal cells as a potential source to form insulin-producing cells. The gastrointestinal tissue is abundant with adult stem/progenitor cells that are continuously forming epithelial cells, including enteroendocrine cells [49,50]. In fetal and adult mice, specific deletion of *FoxO1* in *ngn3*-positive enteroendocrine progenitors converted them into insulin-positive cells [51]. This ablation of the *FoxO1* in the enteroendocrine cells increased the expression of β -cell transcription factors *pdx1*, *ngn3*, *MafA* and *Nkx6.1* [51]. In human pluripotent stem (iPS) cells, *FOXO1* inhibition induced the generation of insulin-producing cells that express all markers of mature pancreatic β cells [52]. Similar to acinar cells and liver cells, forced expression of *ngn3*, *MafA* and *pdx1* in mice intestinal crypt cells and human intestinal organoids converted them to β -like cells [53]. In this study, expression of *ngn3*, *MafA* and *pdx1* in intestinal cells lead to modest but significant improvement in glucose tolerance in Streptozotocin-treated mice [53]. Similarly, forced expression of *ngn3*, *MafA* and *pdx1* reprogrammed gastrointestinal enteroendocrine cells to insulin-producing cells with the highest efficiency being observed in the stomach antrum [54].

One major problem with targeting non-endocrine cells as a source of new insulin-producing cells is that these attempts only resulted in a partial improvement in glycemia, specifically fasting glucose, in diabetic mouse models. The overall glucose tolerance, however, despite the improvement in fasting glucose levels, remained quite abnormal, indicating that the newly formed β -like cells can secrete some basal insulin, but they cannot respond adequately to a glucose challenge, which obviously raises concerns about the potential translatability of this approach.

A second drawback with reprogramming a non-endocrine cell such as an acinar cell to become an insulin-producing cell (or any islet endocrine cell for that matter), *ngn3* is necessary to initiate an endocrine lineage identity and to suppress the acinar cell phenotype [41]. Subsequently, *pdx1* and *MafA* further convert *ngn3* positive cells into insulin-producing cells. Here, the continued expression of *ngn3* in differentiated islet cells is a significant drawback of this approach when trying to generate β cells from non-endocrine cells because *ngn3* expression is normally low or absent from differentiated islet endocrine cells [55]. Thus, the use of a triple transcription factor vector encoding *pdx1*, *MafA* and *ngn3* would lead to constitutive expression of relatively high levels of *ngn3* in the trans-differentiated β -like cells, which may have negative consequences. Thus, targeting endocrine cells seems a preferable approach to regenerating β/β -like cells.

Why α cells may be an optimal source for new β cell formation

Recently, researchers have shifted their focus toward α cells as a source for the replacement of β cells. Several reasons favor α cells as a proper source for β cell replacement compared with non-endocrine cells, including: (1) α and β cell lineages appear to arise from a common precursor [15,56], which may facilitate reprogramming. (2) evidence already exists for the potential interconversion between α and β cells; postnatal deletion of *pdx1* in mouse β cells led to loss of β cells with an increase in α cells, accompanied by a change in islet morphology, with glucagon-positive cells in the periphery and center of the islet, rather than the usual periphery only in mice. In addition, some cells were double-positive for both glucagon and insulin [24]. Also, it is reported that a massive loss of β cells in the adult mouse pancreas led to the conversion of α cells into β cells, again with the appearance of bi-hormonal cells expressing both insulin and glucagon [57], additionally, monoclonal antibodies to glucagon receptor were found to induce α cell hyperplasia and subsequently α cells were converted to β -like cells [58], thus supporting the ability to reprogram α cells into insulin-producing cells therapeutically since it can happen spontaneously. (3) the similarities in the function of α cells and β cells, as both cells have *Slc2a2* transporter that allows glucose sensing within a physiologic range [59]. Also, α cells and β cells have similar machinery to metabolize glucose and secrete hormones [60]. (4) α cells are located anatomically in the islet, receiving the same blood supply [15], additionally, in humans, α and β cells being located in islets, they receive sympathetic nerve supply through the splanchnic nerve with the neural cell bodies originate from the superior mesenteric and celiac ganglia, while the parasympathetic innervation comes from the vagus nerve [61], which is ideal for the optimal function of newly formed β -like cells [62]. (5) α cells represent $\sim 35\%$ of the islet cells in humans [63], which makes them an abundant source for β cell replacement. (6) Reduction in α cell mass in mice does not have a negative impact on glucose metabolism [64]. In view of these reasons, α cell appears to be an ideal therapeutic target for replacement of β cells to treat diabetes.

Therapeutic attempts to reprogram α cells into insulin-producing cells

Several attempts were made to reprogram α cells into insulin-producing cells *ex vivo* and *in vivo*.

For example, *in vivo* forced expression of *pax4* in mouse islet progenitors induced production of α -like cells that then converted into β -like cells, forming large islets with β cell predominance; *ngn3* reactivation was crucial in this process [65]. In this model, the *pax4* forced expression in islets not only increased β cell mass, but led to improved glucose tolerance. Furthermore, the ectopic expression of *pax4* in adult α cells continuously converted them into β cells and reversed hyperglycemia in streptozotocin-treated animals; interestingly, this effect was only seen in mice younger than four weeks [65].

Sangan et al. [66] reprogrammed an α cell line, α TC1.9, into insulin-producing cells by ectopic expression of HNF4 α , which resulted in glucagon suppression and induced a β -like cell phenotype; however, that reprogramming was incomplete because certain β cell-specific transcription factors such as *pdx1* were not induced.

Similarly, Zhang et al. delivered *pax4* via a viral vector (adenovirus 5) into α TC1.9 cells leading to an induction of insulin synthesis and suppression of glucagon. Here, *pax4* expression led to an up-regulation of the β cell transcription factors *pdx1*, *MafA*, *ngn3*, and *nkx 6.1* in the α TC1.9 cells. Also, direct infusion of adenovirus 5 carrying a *pax4* expression cassette into the pancreas via the pancreatic duct resulted in a small improvement in glucose tolerance in toxin-induced diabetic mice, though not a biologically significant improvement [67].

Furthermore, inactivation of *arx* and *dnmt1* in adult mouse pancreatic α cells led to conversion of a subset (50–80% over three months) of these α cells into β -like cells with the capacity to secrete insulin in response to glucose stimulation, yet this insulin secretion capacity was significantly lower than true β cells [68]. Based on the results of that study, a follow up study used the anti-malaria drug artemether to suppress the α cell transcription factor *arx* in mice to promote trans-differentiation into β -like cells [69]. However, the key initial experiments in this study were carried out in islet cell lines, but subsequent validation experiments *in vivo* showed some degree of trans-differentiation, but without a clear demonstration of α to β cell conversion; moreover, artemether was found to abrogate β cell calcium signaling and insulin secretion in response to glucose [70].

In the same context, another study reported that the prolonged exposure of wild-type mice to GABA resulted in the conversion of α cells into β -like cells through the down-regulation of *Arx* expression [71]. In this study GABA treatment successfully reversed hyperglycemia in Streptozotocin-treated mice [71]. Also, Young-sun et al. have shown that glucagon-like peptide 1 promoted the formation of new β -like cells from α cells in mice via FGF21 after chemical ablation of β cells with Streptozotocin [72].

More recently, the focus has shifted to overexpression of *MafA* and *pdx1* in α cells to convert them into β -like cells. In adult mice, induced expression of *MafA* and *pdx1* in *ngn3* positive endocrine progenitor cells led to the development of a β -like cell phenotype; similarly, *pdx1* and *MafA* overexpression in α cells led to its trans-differentiation into β -like cells [73]. This latter study was followed by a study that used an *in vivo* infusion of adeno-associated virus (AAV) carrying *pdx1* and *MafA* expression cassettes into the pancreatic duct, leading to reprogramming of α cells into functional β -like cells with normalization of blood glucose in both β cell-toxin-induced diabetic mice and in autoimmune NOD mice (Figure 2). In that study, the euglycemia persisted in the autoimmune NOD mice for four months before the recurrence of hyperglycemia, perhaps because the immune system began to recognize and destroy the newly formed β -like cells. This gene therapy strategy also induced α to β cell conversion in toxin-treated human islets, which restored blood glucose levels in NOD/SCID mice upon transplantation [74].

A subsequent study sought to better study human islet cell plasticity, specifically the ability of human α cells to transform into β cells. *In vitro* infection of human α -cell-only pseudoislets with adenovirus expressing *PDX1* and *MAFA* led to conversion of ~35% of these α cells into insulin-positive cells [75]. Moreover, transplantation of pseudoislets, made of α cells infected with this same *pdx1* and *MafA* adenovirus, into diabetic immunodeficient NOD/SCID/Il2rg^{-/-} (NSG) mice led to improved insulin secretion and glucose tolerance. The improvement fell short of full normalization, likely due to an inadequate mass of transplanted reprogrammed α cells [75].

A cell to β cell conversion; challenges and future directions

Translation of this therapeutic gene strategy to treat diabetes in humans seems technically applicable via the noninvasive procedure endoscopic retrograde cholangiopancreatography (ERCP). However, finding a proper viral vector that could carry the genes and targets human α cells with high affinity *in vivo* remains a challenge.




Figure 2. In NOD mice with hyperglycemia, pancreatic intraductal infusion of adeno-associated virus-containing *pdx1* and *MafA* converted α cells into β cells and restored normoglycemia.

Thorel et al. [57] found similar α to β cell trans-differentiation de novo after an extreme loss of β cells. However, the conversion and the rescue process took very long time compared with the viral-mediated α to β cell trans-differentiation.

Xiao et al. and Furuyama et al. used AAV serotype 8 virus to deliver *pdx1* and *MafA* to human α cells *ex vivo* [74,75]. However, directly infecting islets *ex vivo* with the virus differs significantly from using an *in vivo* pancreatic duct infusion. In cell culture, the virus is placed in direct contact with the islets, making the pathway to viral infection of the islets very different. *In vivo*, the virus must pass out of the pancreatic ductal system, crossing the pancreatic duct epithelium and ductal basement membrane, or crossing the acinar cells and the acinar basement membrane, across the interstitial space before finally reaching the islets, which also *in vivo* are surrounded by a basement membrane ‘capsule’ [76]. This capsule is degraded during the islet isolation process and therefore not a barrier to *in vitro* islet infection by virus. During this journey, undesirable trapping of the virus in exocrine cells may occur before they can reach the islets and potentially preventing adequate numbers of virus from reaching the α cells. Finding the ideal vector (virus type and serotype) for infecting α cells in humans will likely require further studies in non-human primates. This primate optimization will be necessary before pursuing clinical trials in humans to ensure the safety of the viral therapy, minimizing the risk of adverse extrapancreatic side effects, and optimizing efficacy. Efficacy will entail infecting and reprogramming an adequate number of α cells into insulin-producing cells enough to reverse hyperglycemia.

The immunogenicity of the newly formed β cells from α cells is also an important aspect that needs to be addressed before applying this therapeutic strategy in type 1 diabetes. Xiao et al. have shown that *pdx1* and *MafA* gene therapy maintained euglycemia in NOD mice for four months, suggesting that the newly formed β cells are not quickly recognized by the autoimmune response [74]. Thus, this gene therapy could be combined with immunomodulation or immunosuppression to prolong the lifespan of the newly formed β -like cells.

Studies that examine the efficacy of this therapeutic strategy in treating type 2 diabetes in animal models are still lacking. In both impaired glucose tolerance (prediabetes) and T2D, insulin resistance at the hepatic level and peripheral tissues occurs due to impaired insulin signaling [2,77] and inappropriate hyperglucagonemia [78,79]. With long-standing insulin resistance, there is an eventual decline in β cell mass and function [8]. Considering that the pathophysiology of type 2 diabetes involves a decrease in insulin secretion secondary to decreased β cell mass and function, and inappropriate hyperglucagonemia, the reprogramming of α cells into

insulin-secreting cells seems to be an appealing treatment for this disorder by restoring β cell mass, leading to increased insulin secretion, and by decreasing α cell mass with a potential reduction in the hyperglucagonemia and insulin resistance. Ideally, such a treatment for type 2 diabetes, with the reprogramming of α cells into insulin-producing cells, would be accompanied by lifestyle modification. Otherwise, the persistent chronic exposure of the newly formed β cells to insulin resistance, glucotoxicity and lipotoxicity would likely cause failure of the new β -like cells, with recurrence of hyperglycemia [80]. Thus, more studies are needed to address the potential benefit of using α cell to β cell conversion in treating type 2 diabetes.

Overall, further studies are required to develop and optimize this promising therapeutic strategy given the desperate need to find novel treatments and perhaps a cure for diabetes, a major health and economic problem.

Perspectives

- Importance in the field: Diabetes is a major health and economic problem in the United States and around the world. There is currently no cure for diabetes. Converting α cells into insulin-producing cells could provide a promising therapeutic strategy to cure diabetes.
- Current thinking: The use of viral gene therapy to drive the expression of *pdx1* and *MafA* in α cells, transforming them into functional β cells, has recently become the main direction in this research field. This technique will replace the lost β cell mass and restore insulin secretion capacity in individuals with diabetes.
- Future directions: In this field, future directions include: (1) Developing a proper viral vector that could carry the genes and targets human α cells with high affinity *in vivo*. (2) Immunomodulation to prevent the immune-mediated destruction of the newly formed β cells in type 1 diabetes. (3) Investigate the potential efficacy of this approach as a therapeutic strategy for type 2 diabetes.

Competing Interests

George Gittes has a potential conflict of interest with Genprex company that contributes to supporting his research work about converting alpha cells into beta cells to treat diabetes.

Author Contributions

M.S. and K.P. wrote the review. G.G. reviewed and edited the manuscript.

Funding

This work was partially supported by NIDDK funding to GG (RO1DK111460).

Abbreviations

AAV, adeno-associated virus; NOD, non-obese diabetic; PMN, *pdx1*, *MafA*, and *ngn3*; SCID, severe combined immunodeficient.

References

- 1 Atkinson, M.A., Eisenbarth, G.S. and Michels, A.W. (2014) Type 1 diabetes. *Lancet* **383**, 69–82 [https://doi.org/10.1016/S0140-6736\(13\)60591-7](https://doi.org/10.1016/S0140-6736(13)60591-7)
- 2 DeFronzo, R.A. (2009) Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. *Diabetes* **58**, 773–795 <https://doi.org/10.2337/db09-9028>
- 3 Rahier, J., Guiot, Y., Goebbels, R.M., Sempoux, C. and Henquin, J.C. (2008) Pancreatic beta-cell mass in European subjects with type 2 diabetes. *Diabetes Obes. Metab.* **10**, 32–42 <https://doi.org/10.1111/j.1463-1326.2008.00969.x>
- 4 Yoon, K.H., Ko, S.H., Cho, J.H., Lee, J.M., Ahn, Y.B., Song, K.H. et al. (2003) Selective beta-cell loss and alpha-cell expansion in patients with type 2 diabetes mellitus in Korea. *J. Clin. Endocrinol. Metab.* **88**, 2300–2308 <https://doi.org/10.1210/jc.2002-020735>
- 5 Butler, A.E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R.A. and Butler, P.C. (2003) Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. *Diabetes* **52**, 102–110 <https://doi.org/10.2337/diabetes.52.1.102>

- 6 Weir, G.C., Butler, P.C. and Bonner-Weir, S. (2021) The beta-cell glucose toxicity hypothesis: attractive but difficult to prove. *Metabolism* **124**, 154870 <https://doi.org/10.1016/j.metabol.2021.154870>
- 7 Rege, N.K., Liu, M., Yang, Y., Dhayalan, B., Wickramasinghe, N.P., Chen, Y.S. et al. (2020) Evolution of insulin at the edge of foldability and its medical implications. *Proc. Natl Acad. Sci. U.S.A.* **117**, 29618–29628 <https://doi.org/10.1073/pnas.2010908117>
- 8 Gastaldelli, A., Ferrannini, E., Miyazaki, Y., Matsuda, M. and DeFronzo, R.A. (2004) San Antonio metabolism s. Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. *Diabetologia* **47**, 31–39 <https://doi.org/10.1007/s00125-003-1263-9>
- 9 Abdul-Ghani, M.A., Jenkinson, C.P., Richardson, D.K., Tripathy, D. and DeFronzo, R.A. (2006) Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study. *Diabetes* **55**, 1430–1435 <https://doi.org/10.2337/db05-1200>
- 10 Weyer, C., Bogardus, C., Mott, D.M. and Pratley, R.E. (1999) The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. *J. Clin. Invest.* **104**, 787–794 <https://doi.org/10.1172/JCI7231>
- 11 Del Prato, S. (2003) Loss of early insulin secretion leads to postprandial hyperglycaemia. *Diabetologia* **46**, M2–M8 <https://doi.org/10.1007/s00125-002-0930-6>
- 12 Aguilar, R.B. (2011) Evaluating treatment algorithms for the management of patients with type 2 diabetes mellitus: a perspective on the definition of treatment success. *Clin. Ther.* **33**, 408–424 <https://doi.org/10.1016/j.clinthera.2011.04.008>
- 13 Godinho, R., Mega, C., Teixeira-de-Lemos, E., Carvalho, E., Teixeira, F., Fernandes, R. et al. (2015) The place of dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapeutics: a “me too” or “the special one” antidiabetic class? *J. Diabetes Res.* **2015**, 806979 <https://doi.org/10.1155/2015/806979>
- 14 Marin-Penalver, J.J., Martin-Timon, I., Sevillano-Collantes, C. and Del Canizo-Gomez, F.J. (2016) Update on the treatment of type 2 diabetes mellitus. *World J. Diabetes* **7**, 354–395 <https://doi.org/10.4239/wjcd.v7.i17.354>
- 15 Herrera, P.L. (2000) Adult insulin- and glucagon-producing cells differentiate from two independent cell lineages. *Development* **127**, 2317–2322 <https://doi.org/10.1242/dev.127.11.2317>
- 16 Teitelman, G., Alpert, S., Polak, J.M., Martinez, A. and Hanahan, D. (1993) Precursor cells of mouse endocrine pancreas coexpress insulin, glucagon and the neuronal proteins tyrosine hydroxylase and neuropeptide Y, but not pancreatic polypeptide. *Development* **118**, 1031–1039 <https://doi.org/10.1242/dev.118.4.1031>
- 17 Herrera, P.L., Huarte, J., Sanvito, F., Meda, P., Orci, L. and Vassalli, J.D. (1991) Embryogenesis of the murine endocrine pancreas; early expression of pancreatic polypeptide gene. *Development* **113**, 1257–1265 <https://doi.org/10.1242/dev.113.4.1257>
- 18 Gu, G., Dubauskaite, J. and Melton, D.A. (2002) Direct evidence for the pancreatic lineage: NGN3+ cells are islet progenitors and are distinct from duct progenitors. *Development* **129**, 2447–2457 <https://doi.org/10.1242/dev.129.10.2447>
- 19 Guz, Y., Montminy, M.R., Stein, R., Leonard, J., Garner, L.W., Wright, C.V. et al. (1995) Expression of murine STF-1, a putative insulin gene transcription factor, in beta cells of pancreas, duodenal epithelium and pancreatic exocrine and endocrine progenitors during ontogeny. *Development* **121**, 11–18 <https://doi.org/10.1242/dev.121.1.11>
- 20 Ohlsson, H., Karlsson, K. and Edlund, T. (1993) IPF1, a homeodomain-containing transactivator of the insulin gene. *EMBO J.* **12**, 4251–4259 <https://doi.org/10.1002/j.1460-2075.1993.tb06109.x>
- 21 Hani, E.H., Stoffers, D.A., Chevre, J.C., Durand, E., Stanojevic, V., Dina, C. et al. (1999) Defective mutations in the insulin promoter factor-1 (IPF-1) gene in late-onset type 2 diabetes mellitus. *J. Clin. Invest.* **104**, R41–R48 <https://doi.org/10.1172/JCI7469>
- 22 Stoffers, D.A., Ferrer, J., Clarke, W.L. and Habener, J.F. (1997) Early-onset type-II diabetes mellitus (MODY4) linked to IPF1. *Nat. Genet.* **17**, 138–139 <https://doi.org/10.1038/ng1097-138>
- 23 Gannon, M., Ables, E.T., Crawford, L., Lowe, D., Offield, M.F., Magnuson, M.A. et al. (2008) . pdx-1 function is specifically required in embryonic beta cells to generate appropriate numbers of endocrine cell types and maintain glucose homeostasis. *Dev. Biol.* **314**, 406–417 <https://doi.org/10.1016/j.ydbio.2007.10.038>
- 24 Ahlgren, U., Jonsson, J., Jonsson, L. and Simu, K. (1998) Edlund H. beta-cell-specific inactivation of the mouse *Ipf1/Pdx1* gene results in loss of the beta-cell phenotype and maturity onset diabetes. *Genes Dev.* **12**, 1763–1768 <https://doi.org/10.1101/gad.12.12.1763>
- 25 Gradwohl, G., Dierich, A., LeMeur, M. and Guillemot, F. (2000) neurogenin3 is required for the development of the four endocrine cell lineages of the pancreas. *Proc. Natl Acad. Sci. U.S.A.* **97**, 1607–1611 <https://doi.org/10.1073/pnas.97.4.1607>
- 26 Schwitzgebel, V.M., Scheel, D.W., Connors, J.R., Kalamaras, J., Lee, J.E., Anderson, D.J. et al. (2000) Expression of neurogenin3 reveals an islet cell precursor population in the pancreas. *Development* **127**, 3533–3542 <https://doi.org/10.1242/dev.127.16.3533>
- 27 Jenny, M., Uhl, C., Roche, C., Duluc, I., Guillermin, V., Guillemot, F. et al. (2002) Neurogenin3 is differentially required for endocrine cell fate specification in the intestinal and gastric epithelium. *EMBO J.* **21**, 6338–6347 <https://doi.org/10.1093/emboj/cdf649>
- 28 Sheets, T.P., Park, K.E., Park, C.H., Swift, S.M., Powell, A., Donovan, D.M. et al. (2018) Targeted mutation of NGN3 gene disrupts pancreatic endocrine cell development in pigs. *Sci. Rep.* **8**, 3582 <https://doi.org/10.1038/s41598-018-22050-0>
- 29 Rukstalis, J.M. and Habener, J.F. (2009) Neurogenin3: a master regulator of pancreatic islet differentiation and regeneration. *Islets* **1**, 177–184 <https://doi.org/10.4161/isl.1.3.9877>
- 30 Vanhoose, A.M., Samaras, S., Artner, I., Henderson, E., Hang, Y. and Stein, R. (2008) MafA and MafB regulate Pdx1 transcription through the Area II control region in pancreatic beta cells. *J. Biol. Chem.* **283**, 22612–22619 <https://doi.org/10.1074/jbc.M802902200>
- 31 Artner, I., Hang, Y., Mazur, M., Yamamoto, T., Guo, M., Lindner, J. et al. (2010) MafA and MafB regulate genes critical to beta-cells in a unique temporal manner. *Diabetes* **59**, 2530–2539 <https://doi.org/10.2337/db10-0190>
- 32 Hang, Y. and Stein, R. (2011) MafA and MafB activity in pancreatic beta cells. *Trends Endocrinol. Metab.* **22**, 364–373 <https://doi.org/10.1016/j.tem.2011.05.003>
- 33 Nishimura, W., Bonner-Weir, S. and Sharma, A. (2009) Expression of MafA in pancreatic progenitors is detrimental for pancreatic development. *Dev. Biol.* **333**, 108–120 <https://doi.org/10.1016/j.ydbio.2009.06.029>
- 34 Conrad, E., Dai, C., Spaeth, J., Guo, M., Cyphert, H.A., Scoville, D. et al. (2016) The MAFB transcription factor impacts islet alpha-cell function in rodents and represents a unique signature of primate islet beta-cells. *Am. J. Physiol. Endocrinol. Metab.* **310**, E91–E102 <https://doi.org/10.1152/ajpendo.00285.2015>

- 35 Artner, I., Bianchi, B., Raum, J.C., Guo, M., Kaneko, T., Cordes, S. et al. (2007) MafB is required for islet beta cell maturation. *Proc. Natl Acad. Sci. U.S.A.* **104**, 3853–3858 <https://doi.org/10.1073/pnas.0700013104>
- 36 Rall, L.B., Pictet, R.L., Williams, R.H. and Rutter, W.J. (1973) Early differentiation of glucagon-producing cells in embryonic pancreas: a possible developmental role for glucagon. *Proc. Natl Acad. Sci. U.S.A.* **70**, 3478–3482 <https://doi.org/10.1073/pnas.70.12.3478>
- 37 Murtaugh, L.C. (2007) Pancreas and beta-cell development: from the actual to the possible. *Development* **134**, 427–438 <https://doi.org/10.1242/dev.02770>
- 38 Cozar-Castellano, I. and Stewart, A.F. (2005) Molecular engineering human hepatocytes into pancreatic beta cells for diabetes therapy. *Proc. Natl Acad. Sci. U.S.A.* **102**, 7781–7782 <https://doi.org/10.1073/pnas.0503261102>
- 39 Hao, E., Tyrberg, B., Itkin-Ansari, P., Lakey, J.R., Geron, I., Monosov, E.Z. et al. (2006) Beta-cell differentiation from nonendocrine epithelial cells of the adult human pancreas. *Nat. Med.* **12**, 310–316 <https://doi.org/10.1038/nm1367>
- 40 McKimpson, W.M. and Accili, D. (2019) Reprogramming cells to make insulin. *J. Endocr. Soc.* **3**, 1214–1226 <https://doi.org/10.1210/js.2019-00040>
- 41 Li, W., Nakanishi, M., Zumsteg, A., Shear, M., Wright, C., Melton, D.A. et al. (2014) *In vivo* reprogramming of pancreatic acinar cells to three islet endocrine subtypes. *eLife* **3**, e01846 <https://doi.org/10.7554/eLife.01846>
- 42 Zhou, Q., Brown, J., Kanarek, A., Rajagopal, J. and Melton, D.A. (2008) *In vivo* reprogramming of adult pancreatic exocrine cells to beta-cells. *Nature* **455**, 627–632 <https://doi.org/10.1038/nature07314>
- 43 Sapor, T., Shternhall, K., Meivar-Levy, I., Blumenfeld, T., Cohen, H., Skutelsky, E. et al. (2005) Cell-replacement therapy for diabetes: generating functional insulin-producing tissue from adult human liver cells. *Proc. Natl Acad. Sci. U.S.A.* **102**, 7964–7969 <https://doi.org/10.1073/pnas.0405277102>
- 44 Ferber, S., Halkin, A., Cohen, H., Ber, I., Einav, Y., Goldberg, I. et al. (2000) Pancreatic and duodenal homeobox gene 1 induces expression of insulin genes in liver and ameliorates streptozotocin-induced hyperglycemia. *Nat. Med.* **6**, 568–72 <https://doi.org/10.1038/75050>
- 45 Aviv, V., Meivar-Levy, I., Rachmut, I.H., Rubinek, T., Mor, E. and Ferber, S. (2009) Exendin-4 promotes liver cell proliferation and enhances the PDX-1-induced liver to pancreas transdifferentiation process. *J. Biol. Chem.* **284**, 33509–33520 <https://doi.org/10.1074/jbc.M109.017608>
- 46 Cim, A., Sawyer, G.J., Zhang, X., Su, H., Collins, L., Jones, P. et al. (2012) *In vivo* studies on non-viral transdifferentiation of liver cells towards pancreatic beta cells. *J. Endocrinol.* **214**, 277–288 <https://doi.org/10.1530/JOE-12-0033>
- 47 Banga, A., Akinci, E., Greder, L.V., Dutton, J.R. and Slack, J.M. (2012) *In vivo* reprogramming of Sox9+ cells in the liver to insulin-secreting ducts. *Proc. Natl Acad. Sci. U.S.A.* **109**, 15336–15341 <https://doi.org/10.1073/pnas.1201701109>
- 48 Banga, A., Greder, L.V., Dutton, J.R. and Slack, J.M. (2014) Stable insulin-secreting ducts formed by reprogramming of cells in the liver using a three-gene cocktail and a PPAR agonist. *Gene Ther.* **21**, 19–27 <https://doi.org/10.1038/gt.2013.50>
- 49 Barker, N., van Es, J.H., Kuipers, J., Kujala, P., van den Born, M., Cozijnsen, M. et al. (2007) Identification of stem cells in small intestine and colon by marker gene Lgr5. *Nature* **449**, 1003–1007 <https://doi.org/10.1038/nature06196>
- 50 Barker, N., Huch, M., Kujala, P., van de Wetering, M., Snippert, H.J., van Es, J.H. et al. (2010) Lgr5(+ve) stem cells drive self-renewal in the stomach and build long-lived gastric units in vitro. *Cell Stem Cell* **6**, 25–36 <https://doi.org/10.1016/j.stem.2009.11.013>
- 51 Talchai, C., Xuan, S., Kitamura, T., DePinho, R.A. and Accili, D. (2012) Generation of functional insulin-producing cells in the gut by Foxo1 ablation. *Nat. Genet.* **44**, 406–412. S1 <https://doi.org/10.1038/ng.2215>
- 52 Bouchi, R., Foo, K.S., Hua, H., Tsuchiya, K., Ohmura, Y., Sandoval, P.R. et al. (2014) FOXO1 inhibition yields functional insulin-producing cells in human gut organoid cultures. *Nat. Commun.* **5**, 4242 <https://doi.org/10.1038/ncomms5242>
- 53 Chen, Y.J., Finkbeiner, S.R., Weinblatt, D., Emmett, M.J., Tameire, F., Yousefi, M. et al. (2014) De novo formation of insulin-producing “neo-beta cell islets” from intestinal crypts. *Cell Rep.* **6**, 1046–1058 <https://doi.org/10.1016/j.celrep.2014.02.013>
- 54 Ariyachet, C., Tovaglieri, A., Xiang, G., Lu, J., Shah, M.S., Richmond, C.A. et al. (2016) Reprogrammed stomach tissue as a renewable source of functional beta cells for blood glucose regulation. *Cell Stem Cell* **18**, 410–421 <https://doi.org/10.1016/j.stem.2016.01.003>
- 55 Gomez, D.L., O’Driscoll, M., Sheets, T.P., Hruban, R.H., Oberholzer, J., McGarrigle, J.J. et al. (2015) Neurogenin 3 expressing cells in the human exocrine pancreas have the capacity for endocrine cell fate. *PLoS ONE* **10**, e0133862 <https://doi.org/10.1371/journal.pone.0133862>
- 56 Bonal, C. and Herrera, P.L. (2008) Genes controlling pancreas ontogeny. *Int. J. Dev. Biol.* **52**, 823–835 <https://doi.org/10.1387/ijdb.072444cb>
- 57 Thorel, F., Nepote, V., Avril, I., Kohno, K., Desgraz, R., Chera, S. et al. (2010) Conversion of adult pancreatic alpha-cells to beta-cells after extreme beta-cell loss. *Nature* **464**, 1149–1154 <https://doi.org/10.1038/nature08894>
- 58 Wei, R., Gu, L., Yang, J., Yang, K., Liu, J., Le, Y. et al. (2019) Antagonistic glucagon receptor antibody promotes alpha-cell proliferation and increases beta-cell mass in diabetic mice. *iScience* **16**, 326–339 <https://doi.org/10.1016/j.isci.2019.05.030>
- 59 Quesada, I., Tuduri, E., Ripoll, C. and Nadal, A. (2008) Physiology of the pancreatic alpha-cell and glucagon secretion: role in glucose homeostasis and diabetes. *J. Endocrinol.* **199**, 5–19 <https://doi.org/10.1677/JOE-08-0290>
- 60 Zhang, Q., Ramrachaya, R., Lahmann, C., Tarasov, A., Bengtsson, M., Braha, O. et al. (2013) Role of KATP channels in glucose-regulated glucagon secretion and impaired counterregulation in type 2 diabetes. *Cell Metab.* **18**, 871–882 <https://doi.org/10.1016/j.cmet.2013.10.014>
- 61 Salviooli, B., Bovera, M., Barbara, G., De Ponti, F., Stanghellini, V., Tonini, M. et al. (2002) Neurology and neuropathology of the pancreatic innervation. *JOP* **3**, 26–33 PMID:11884764
- 62 Pipeleers, D., Keymeulen, B., Chatenoud, L., Hendrieckx, C., Ling, Z., Mathieu, C. et al. (2002) A view on beta cell transplantation in diabetes. *Ann. N. Y. Acad. Sci.* **958**, 69–76 <https://doi.org/10.1111/j.1749-6632.2002.tb02948.x>
- 63 Steiner, D.J., Kim, A., Miller, K. and Hara, M. (2010) Pancreatic islet plasticity: interspecies comparison of islet architecture and composition. *Islets* **2**, 135–145 <https://doi.org/10.4161/isl.2.3.11815>
- 64 Shiota, C., Prasadana, K., Guo, P., El-Gohary, Y., Wiersch, J., Xiao, X. et al. (2013) . alpha-Cells are dispensable in postnatal morphogenesis and maturation of mouse pancreatic islets. *Am. J. Physiol. Endocrinol. Metab.* **305**, E1030–E1040 <https://doi.org/10.1152/ajpendo.00022.2013>
- 65 Collombat, P., Xu, X., Ravassard, P., Sosa-Pineda, B., Dussaud, S., Billestrup, N. et al. (2009) The ectopic expression of Pax4 in the mouse pancreas converts progenitor cells into alpha and subsequently beta cells. *Cell* **138**, 449–462 <https://doi.org/10.1016/j.cell.2009.05.035>
- 66 Sangani, C.B., Jover, R., Heimberg, H. and Tosh, D. (2015) *In vitro* reprogramming of pancreatic alpha cells towards a beta cell phenotype following ectopic HNF4alpha expression. *Mol. Cell. Endocrinol.* **399**, 50–59 <https://doi.org/10.1016/j.mce.2014.09.009>

- 67 Zhang, Y., Fava, G.E., Wang, H., Mauvais-Jarvis, F., Fonseca, V.A. and Wu, H. (2016) PAX4 gene transfer induces alpha-to-beta cell phenotypic conversion and confers therapeutic benefits for diabetes treatment. *Mol. Ther.* **24**, 251–260 <https://doi.org/10.1038/mt.2015.181>
- 68 Chakravarthy, H., Gu, X., Enge, M., Dai, X., Wang, Y., Damond, N. et al. (2017) Converting adult pancreatic islet alpha cells into beta cells by targeting both Dnmt1 and Arx. *Cell Metab.* **25**, 622–634 <https://doi.org/10.1016/j.cmet.2017.01.009>
- 69 Li, J., Casteels, T., Frogne, T., Ingvorsen, C., Honore, C., Courtney, M. et al. (2017) Artemisinins target GABAA receptor signaling and impair alpha cell identity. *Cell* **168**, 86–100 e15 <https://doi.org/10.1016/j.cell.2016.11.010>
- 70 van der Meulen, T., Lee, S., Noordeloos, E., Donaldson, C.J., Adams, M.W., Noguchi, G.M. et al. (2018) Artemether does not turn alpha cells into beta cells. *Cell Metab.* **27**, 218–225 e4 <https://doi.org/10.1016/j.cmet.2017.10.002>
- 71 Ben-Othman, N., Vieira, A., Courtney, M., Record, F., Gjernes, E., Avolio, F. et al. (2017) Long-term GABA administration induces alpha cell-mediated beta-like cell neogenesis. *Cell* **168**, 73–85 e11 <https://doi.org/10.1016/j.cell.2016.11.002>
- 72 Lee, Y.S., Shin, S., Shigihara, T., Hahm, E., Liu, M.J., Han, J. et al. (2007) Glucagon-like peptide-1 gene therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis. *Diabetes* **56**, 1671–1679 <https://doi.org/10.2337/db06-1182>
- 73 Matsuoka, T.A., Kawashima, S., Miyatsuka, T., Sasaki, S., Shimo, N., Katakami, N. et al. (2017) MafA enables Pdx1 to effectively convert pancreatic islet progenitors and committed islet alpha-cells into beta-cells *in vivo*. *Diabetes* **66**, 1293–1300 <https://doi.org/10.2337/db16-0887>
- 74 Xiao, X., Guo, P., Shiota, C., Zhang, T., Coudriet, G.M., Fischbach, S. et al. (2018) Endogenous reprogramming of alpha cells into beta cells, induced by viral gene therapy, reverses autoimmune diabetes. *Cell Stem Cell* **22**, 78–90 e4 <https://doi.org/10.1016/j.stem.2017.11.020>
- 75 Furuyama, K., Chera, S., van Gurp, L., Oropeza, D., Ghila, L., Damond, N. et al. (2019) Diabetes relief in mice by glucose-sensing insulin-secreting human alpha-cells. *Nature* **567**, 43–48 <https://doi.org/10.1038/s41586-019-0942-8>
- 76 Korpos, E., Kadri, N., Kappelhoff, R., Wegner, J., Overall, C.M., Weber, E. et al. (2013) The peri-islet basement membrane, a barrier to infiltrating leukocytes in type 1 diabetes in mouse and human. *Diabetes* **62**, 531–542 <https://doi.org/10.2337/db12-0432>
- 77 Henry, R.R., Wallace, P. and Olefsky, J.M. (1986) Effects of weight loss on mechanisms of hyperglycemia in obese non-insulin-dependent diabetes mellitus. *Diabetes* **35**, 990–998 <https://doi.org/10.2337/diab.35.9.990>
- 78 DeFronzo, R.A. and Ferrannini, E. (1987) Regulation of hepatic glucose metabolism in humans. *Diabetes Metab. Rev.* **3**, 415–459 <https://doi.org/10.1002/dmr.5610030204>
- 79 Consoli, A., Nurjhan, N., Reilly, Jr, J.J., Bier, D.M. and Gerich, J.E. (1990) Mechanism of increased gluconeogenesis in noninsulin-dependent diabetes mellitus. Role of alterations in systemic, hepatic, and muscle lactate and alanine metabolism. *J. Clin. Invest.* **86**, 2038–2045 <https://doi.org/10.1172/JCI114940>
- 80 Kahn, S.E., Hull, R.L. and Utzschneider, K.M. (2006) Mechanisms linking obesity to insulin resistance and type 2 diabetes. *Nature* **444**, 840–846 <https://doi.org/10.1038/nature05482>